Crossmark

Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis

Crossref DOI link: https://doi.org/10.1186/s12872-024-04321-z

Published Online: 2024-11-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zhang, Shengxuan

Sun, Lei

Xu, Xinyu

Zhang, Yanling

Chen, Qilan
License Information

Text and Data Mining valid from 2024-11-09

Version of Record valid from 2024-11-09
More Information

Article History

Received: 26 June 2024

Accepted: 4 November 2024

First Online: 9 November 2024

Declarations

:

: This is a systematic review and meta-analysis, ethics approval and consent to participate are not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below